Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 9/20 | 0.36 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1199386 | 0.87 | AHR (0.36) | TBXAS1CYP24A1AHRALDH1A1CYP17A1 | |
| SCHEMBL29247460 | 0.85 | CYP24A1 (0.35) | TBXAS1CYP24A1AHRALDH1A1GPR119 | |
| SCHEMBL17026721 | 0.84 | TBXAS1 (0.37) | TBXAS1CYP24A1AHR | |
| SCHEMBL13479037 | 0.84 | TBXAS1 (0.35) | TBXAS1CYP24A1ALDH1A1GPR119 | |
| SCHEMBL217823 | 0.82 | GPR119 (0.42) | TBXAS1CYP24A1CYP17A1GPR119 | |
| SCHEMBL6094444 | 0.81 | CYP24A1 (0.33) | TBXAS1CYP24A1ALDH1A1GPR119 | |
| SCHEMBL16391056 | 0.79 | CYP24A1 (0.32) | TBXAS1CYP24A1 | |
| SCHEMBL26596807 | 0.79 | TBXAS1 (0.35) | TBXAS1CYP24A1ALDH1A1GPR119LMNA | |
| SCHEMBL23604883 | 0.78 | AHR (0.31) | TBXAS1CYP24A1AHR | |
| SCHEMBL19152231 | 0.77 | CYP24A1 (0.35) | TBXAS1CYP24A1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11799133-B2 | Non-aqueous electrolyte solution for lithium secondary battery and lithium secondary battery including the same | LG ENERGY SOLUTION, LTD. | 2023-10-24 | — | — | US | disclosed |
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| WO-2023055920-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| EP-0236888-B1 | PROCESS FOR BLOCKING AMINO ACIDS WITH THE TERTIARY-ALKOXY-CARBONYL GROUP | PPG INDUSTRIES, INC. (US) | 1990-11-14 | — | — | EP | disclosed |
| US-4837332-A | REACTING AMINE SALT OF AMINO ACID WITH TERTIARY ALKOXYCARBONYLIMIDAZOLE IN SPECIFIC INERT SOLVENT | PPG INDUSTRIES, INC. (US) | 1989-06-06 | — | — | US | disclosed |
| EP-0236888-A1 | Process for blocking amino acids with the tertiary-alkoxy-carbonyl group | PPG INDUSTRIES, INC. (US) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780844-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | TBXAS1 1151/4885CYP24A1 1821/4885AHR 3343/4885 |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TBXAS1 1151/4885CYP24A1 1821/4885AHR 3343/4885 |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TBXAS1 1151/4885CYP24A1 1821/4885AHR 3343/4885 |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TBXAS1 1151/4885CYP24A1 1821/4885AHR 3343/4885 |
| US-11799133-B2 | Non-aqueous electrolyte solution for lithium secondary battery and lithium secondary battery including the same | CACNA1S, PDHB, CACNA1F | TBXAS1 4114/4885CYP24A1 1038/4885AHR 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.